Project Grant R03TR005313
Award Date
6/15/25
Completion Date
6/14/26
Dollars Obligated
$158K
Federal Agency
National Center for Advancing Translational Sciences
Federal Grant Program
93.350
Assistance Type
Project Grant
Place of Performance
Ohio, USA
Similar Awards
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $711,039 Project Grant (CFDA 93.837 - Cardiovascular Diseases Research) to the Research Institute at Nationwide Children's Hospital (RINCH) to investigate the role of cardiac m6A methyltransferases in the pathogenesis of fetal dilated cardiomyopathy (DCM). The project aims to determine the functions of METTL3 and METTL14 in embryonic mouse myocardium and whether their loss in cardiomyocytes induces fetal DCM. It will also identify...
The National Heart, Lung, and Blood Institute (NHLBI), a division of the National Institutes of Health (NIH), awarded a $243,000 project grant under the Cardiovascular Diseases Research program (CFDA 93.837) to the University of Cincinnati. The 2-year award, spanning January 1, 2025 to December 31, 2026, aims to engineer novel RNA biodevices that integrate CRISPR and ADAR gene-editing technologies. This innovative approach seeks to enhance the efficiency and specificity of converting cardiac...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $678,445 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to the University of Maryland, Baltimore to investigate the role of the novel regulator C5ORF51 (C5X) in cardiomyocyte function and homeostasis. The grant supports research to determine the mechanisms by which C5X modulates cardiac transcription and examine its impact on adult cardiomyocyte proliferation and maturation. A sub-award of $TBD was...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $615,006 to the University of Connecticut Health Center (UCHC) to study variants of unknown significance (VUS) in the TNNT2 gene, which is associated with heart failure. The key objectives are to reclassify the pathogenicity of all known TNNT2 VUS and identify their underlying pathophysiology. This will involve comprehensive functional...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research Program (CFDA 93.837), provides $2,044,805 to Case Western Reserve University to advance the understanding of molecular mechanisms underlying genetic cardiac myosin binding protein C (cMyBP-C) cardiomyopathies. The 4-year research project integrates experimental approaches across molecular biology, biophysics, animal physiology, and computer modeling to...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), supports research to investigate the underlying cellular and molecular mechanisms of left ventricular noncompaction cardiomyopathy (LVNC). The $683,048 award, with a performance period from May 1, 2025 to March 31, 2030, will be used by the Research Institute at Nationwide Children's Hospital, a non-profit research organization, to study...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $435,804 Project Grant under the Cardiovascular Diseases Research (CFDA 93.837) program to Childrens Hospital Medical Center in Cincinnati, Ohio. The grant will fund research to elucidate the mechanistic basis for the selective advantage of the acquired DDX41R525H mutation in hematopoietic stem cells (HSCs) of patients with germline DDX41 mutations, who develop myelodysplastic syndrome (MDS) and related myeloid malignancies. The...
This $2,389,542 federal Project Grant award was provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research (CFDA 93.837) program. The grant funds research to investigate the mechanisms by which CFTR correctors, a type of cystic fibrosis treatment, modulate the activity of calcium-activated potassium (KCa) channels. The research aims to define how CFTR correctors inhibit the intermediate conductance KCa3.1 channel and potentiate the large...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $680,831 Project Grant (CFDA 93.837 - Cardiovascular Diseases Research) to the University of Connecticut Health Center (UCHC) to investigate the role of the TRPM7 protein in cardiac fibrosis and heart disease. The project aims to determine whether the channel or kinase functions of TRPM7 contribute to fibrosis, and how inhibiting these functions can protect the heart. The research will use mouse models, molecular biology, and...
This $110,000 Project Grant award from the National Center for Advancing Translational Sciences (NCATS) under CFDA 93.350 supports research by Greenstone Biosciences, Inc. to develop advanced drug discovery and development technologies for rare genetic disorders. The project aims to leverage induced pluripotent stem cell (iPSC) technology and artificial intelligence/machine learning (AI/ML) to accelerate and streamline the drug discovery process for myotonic dystrophy type 1 (DM1), a rare and...